In a powerful show of support for mental health innovation, San Francisco-based public benefit corporation Osmind Inc. announced this week that it has secured 40 million dollars in Series B funding. The company, which builds a specialized mental health EHR system designed for treatment and research, will use the funding to enhance its platform, expand its research collaborations, and double its workforce.
The round was led by DFJ Growth, with participation from new investors Susa Ventures, Lachy Groom, Brent Saunders, Helena Goodman, and Ariel Katz. Previous backers such as General Catalyst, Future Ventures, Tiger Global, and Pear VC also contributed. DFJ Growth partner Justin Kao, co-founder of Helix, will join Osmind’s board of directors.
This funding underscores investor confidence in the company’s unique approach to improving psychiatric care through cutting-edge technology, real-world data, and precision psychiatry.
A Platform Built for a Purpose
Founded in 2020 by Lucia Huang and her team, Osmind is a mission-driven company offering a purpose-built mental health EHR. Unlike general-purpose EHR platforms, Osmind’s software supports clinicians treating moderate to severe mental illness, including depression, suicidality, PTSD, anxiety, OCD, and substance use disorders.
“Mental health clinicians are at the forefront of a powerful transformation,” Huang stated. “We are at a tipping point in psychiatric innovation, much like precision oncology’s evolution in the past two decades.”
Osmind’s mental health EHR helps streamline clinical workflows while integrating features tailored for psychiatric care and emerging treatments like ketamine therapy, esketamine, and transcranial magnetic stimulation (TMS). These capabilities make the platform especially useful for clinics adopting new therapeutic modalities in treatment-resistant populations.
Advancing Research with Real-World Data
One of Osmind’s most impactful innovations is how it connects mental health EHR usage with real-world research. Through its clinician network and anonymized data, Osmind supports large-scale studies that track treatment outcomes over time. Providers can opt into the Osmind Research Program, helping generate valuable insights into what therapies work—and for whom.
In a major collaborative study with Stanford University School of Medicine, results published in The Journal of Affective Disorders revealed that 53.6% of patients receiving ketamine IV therapy (KIT) reported a sustained antidepressant response 14–31 days after a treatment series. The study also found that 73% of participants experiencing suicidal ideation showed symptom improvement. Osmind described this as the largest real-world analysis of KIT outcomes to date, made possible through its mental health EHR data platform.
Building a Network of Trusted Partnerships
Osmind is forging partnerships to advance research and expand access to care. The company works with:
- Fluence, a leader in psychedelic treatment training and research
- The Ketamine Taskforce, which advocates for safe, accessible psychedelic therapies and insurance reimbursement
These collaborations strengthen the company’s ability to support both clinical innovation and policy advocacy. With the mental health EHR serving as the technological backbone, Osmind enables clinicians to track, analyze, and report on emerging therapies in real-time, contributing to best practices and clinical guidelines.
Meeting an Urgent Need for Better Mental Health Solutions
The need for effective mental health treatment has never been more urgent. Depression, suicide, anxiety, and substance use continue to rise, and many existing therapies have limited success for people with treatment-resistant conditions. This is where Osmind’s vision of a research-driven mental health EHR becomes even more critical.
By providing tools that integrate advanced data analytics, precise documentation, and patient-centered features, the platform empowers clinicians to improve outcomes and contribute to a broader scientific understanding of mental illness.
DFJ Growth partner Justin Kao emphasized the gravity and potential of Osmind’s work: “To see neurology, pharmacology, and physiology all advancing at the same time gives me great hope that we’re at the start of a major transformation for psychiatric conditions that are some of the most deadly and disabling in the world.”
Positioning Osmind in a Growing Market
Osmind’s momentum comes amid growing investor interest in digital behavioral health. In 2021, digital mental health companies raised over 5.1 billion dollars, according to a Rock Health report. But while many startups focus on wellness or telehealth, Osmind stands apart by building infrastructure that supports both clinical care and scientific research.
Its mental health EHR isn’t just a record-keeping tool—it’s a collaborative hub for clinicians, researchers, and health systems seeking to close the gap between innovation and impact. The funding will allow Osmind to expand this vision, enhance its features, and grow its team to better support its users.
Looking Ahead
With its 40 million dollar Series B, Osmind is well-positioned to lead the next wave of innovation in psychiatric care. The company plans to invest in platform development, deepen its network of research partners, and expand its workforce to accelerate adoption of its mental health EHR across the country.
As new therapies gain traction and research continues to evolve, Osmind is helping to ensure that mental health care is evidence-based, accessible, and guided by data. The road ahead is challenging, but with continued support and a clear mission, Osmind is building a foundation that could redefine how mental health is treated for generations to come.
